SAB Biotherapeutics (SABS) & Its Peers Head to Head Contrast\n\nPosted by Defense World Staff on Apr 17th, 2025\n\nSAB Biotherapeutics (NASDAQ:SABS – Get Free Report) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare SAB Biotherapeutics to related companies based on the strength of its analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.\n\n**Institutional & Insider Ownership**\n\n7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.\n\n**Earnings & Valuation**\n\nThis table compares SAB Biotherapeutics and its competitors top-line revenue, earnings per share and valuation.\n\n| Gross Revenue | Net Income | Price/Earnings Ratio |\n|---------------|------------|----------------------|\n| SAB Biotherapeutics | $2.24 million | -$42.19 million | -0.38 |\n| SAB Biotherapeutics Competitors | $575.27 million | -$70.96 million | 0.04 |\n\nSAB Biotherapeutics’ competitors have higher revenue, but lower earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.\n\n**Profitability**\n\nThis table compares SAB Biotherapeutics and its competitors’ net margins, return on equity and return on assets.\n\n| Net Margins | Return on Equity | Return on Assets |\n|-------------|------------------|------------------|\n| SAB Biotherapeutics | -1,450.14% | -94.37% | -67.26% |\n| SAB Biotherapeutics Competitors | -2,185.76% | -161.46% | -40.62% |\n\n**Volatility & Risk**\n\nSAB Biotherapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics’ competitors have a beta of -4.48, meaning that their average stock price is 548% less volatile than the S&P 500.\n\n**Analyst Recommendations**\n\nThis is a summary of current ratings for SAB Biotherapeutics and its competitors, as provided by MarketBeat.com.\n\n| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |\n|--------------|--------------|-------------|--------------------|---------------|\n| SAB Biotherapeutics | 0 | 0 | 5 | 3.00 |\n| SAB Biotherapeutics Competitors | 1950 | 5423 | 14013 | 300 | 2.58 |\n\nSAB Biotherapeutics presently has a consensus target price of $11.40, suggesting a potential upside of 720.14%. As a group, “Biological products, except diagnostic” companies have a potential upside of 131.13%. Given SAB Biotherapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe SAB Biotherapeutics is more favorable than its competitors.\n\n**Summary**\n\nSAB Biotherapeutics beats its competitors on 8 of the 13 factors compared.\n\n**SAB Biotherapeutics Company Profile**\n\nSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

SAB Biotherapeutics (SABS) & Its Peers Head to Head Contrast

This article compares SAB Biotherapeutics (NASDAQ:SABS) to other companies in the 'Biological products, except diagnostic' industry based on factors such as institutional ownership, earnings, valuation, profitability, risk, and analyst recommendations. SAB Biotherapeutics has a lower price-to-earnings ratio and stronger analyst ratings compared to its competitors, indicating a potential for higher returns.